Detailed report at: http://www.reportsandintelligence.com/noninvasive-cancer-diagnostics-market Non-invasive diagnostic is a process of identifying the disease conditions with minimal incision in body during diagnosis. The global market for diagnostic/in-vitro diagnostics valued at $49.2 billion in 2012, which shows potential for market growth, especially in chronic diseases. Non-invasive cancer diagnostics is gaining importance over conventional diagnosis due to increase in incidences of chronic cancer such as breast cancer, and lung cancer. Inquire for sample request at: http://www.reportsandintelligence.com/purchase-enquiry/21952 According to American Cancer Society, there were more than 1,660,290 new cases diagnosed in 2013. Commercialization of non-invasive cancer diagnosis is possible due to completion of Human Genome Project (HGP) that gives enormous diagnostic information based on genomic and proteomic. Increase in stringent regulatory guidelines and cost associated with diagnostics is hindering the growth of non-invasive cancer diagnostic market. Web link: http://www.reportsandintelligence.com/

1. Noninvasive Cancer Diagnostics and Technologies
Market - Global Share, Industry Overview,
Analysis, Growth, Trends Opportunities and
Forecast 2012 - 2020
Contact Us: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Mail us: sales@reportsandintelligence.com
Detailed report at:
http://www.reportsandintelligence.com/noninvasive-cancer-diagnostics-
market

2. Non-invasive diagnostic is a process of identifying the disease conditions with
minimal incision in body during diagnosis. The global market for diagnostic/in-vitro
diagnostics valued at $49.2 billion in 2012, which shows potential for market
growth, especially in chronic diseases. Non-invasive cancer diagnostics is gaining
importance over conventional diagnosis due to increase in incidences of chronic
cancer such as breast cancer, and lung cancer. According to American Cancer
Society, there were more than 1,660,290 new cases diagnosed in 2013.
Commercialization of non-invasive cancer diagnosis is possible due to completion
of Human Genome Project (HGP) that gives enormous diagnostic information
based on genomic and proteomic. Increase in stringent regulatory guidelines and
cost associated with diagnostics is hindering the growth of non-invasive cancer
diagnostic market. The Ovarian Cancer National Alliance regulations for
monitoring non-invasive diagnostics are issued by FDA, Medicare and Medicaid
Services (CMS) and Social Security Administration (SSA).
The global non-invasive market has a huge potential in developing countries;
however, cost of diagnosis is creating hurdles to tap this market. Hence, to
overcome this problem, the diagnostic market has to be analyzed by the
developing countries such as China, Japan, and India. This report provides key
market drivers that are driving the market with impact analysis. The report gives
intelligence about key regulatory guidelines issued by respective governments.
Key companies included in report are Precision Therapeutics, A&G
Pharmaceutical, Affymetrix Inc., AVIVA Biosciences Corporation, BIOVIEW Inc.,
Laboratory Corporation of America Holdings (LabCorp), , Quest Diagnostics
Incorporated Cancer Genetics Inc., Digene Corporation, Gen-Probe Incorporated
KEY BENEFITS
 Key developmental strategies adopted by top market players engaged in
this business so that companies involved in development non-invasive
cancer diagnostic device can get competitive intelligence of their
competitors
 Market estimation for therapeutics techniques and geographic segment is
derived from current market scenario and expected market trends

3.  Market attractiveness analysis has been included for various product
segments, therapeutics, techniques and geographic regions with detailed
analysis of factors responsible for rapid growth of the market segments
 In depth analysis of key market drivers, restraints and opportunities of non-invasive
cancer diagnostic market with impact analysis
 Value chain analysis, Porter’s five force model, top investment pockets (GE9
Cell Matrix) are analyzed and presented in detail in the report so that the
decision makers can receive clear picture of cancer diagnosis market
KEY MARKET SEGMENTS
GLOBAL MARKET, BY THERAPEUTICS
• Solid tumors
• Blood cancer
• Lung Cancer
• Breast Cancer
• Others
GLOBAL MARKET, BY TECHNIQUES
• Clinical Chemistry
• Immunochemistry/Immunoassay
• Molecular Diagnostics
• Other Clinical Instruments
GLOBAL MARKET, BY GEOGRAPHY
• North America
• Europe
• Asia-Pacific
• RoW
KEY AUDIENCES
• Medical devices manufacturing companies
• Pharmaceutical companies
• Government and Private Research Institutes
• Academic Institutes

4. Contact Us:
Sona Padman
5320 SW Macadam Avenue,
Suite 100, Portland, OR 97239
United States
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Fax: +1 (855) 550-5975
Email: sales@reportsandintelligence.com
Web: http://www.reportsandintelligence.com/